Physician profile
Paul Wolfe
NPI 1669410411
$6,567.27
in general payments reported to CMS, 2019-2025
29 companies · $948 in 2025
The $948 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $700 · 2021: $1,064 · 2022: $1,126 · 2023: $1,137 · 2024: $1,308 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,393.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,842.44 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Corium, LLC | $1,341.55 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $1,004.02 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $536.09 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $270.73 | 2020-2021 | |
| Sanofi Pasteur INC. | $248.39 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $158.52 | 2019-2024 | |
| Adlon Therapeutics L.P. | $158.44 | 2019-2020 | |
| Neurelis, INC. | $134.75 | 2025 | Valtoco |
| Pfizer INC. | $124.11 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $92.08 | 2023-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $67.93 | 2024-2025 | |
| Seqirus USA INC | $67.22 | 2022-2025 | Flucelvax |
| Neos Therapeutics, LP | $65.10 | 2019-2022 | |
| Genentech USA, INC. | $62.53 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $51.24 | 2019-2025 | Relexxii |
| Masimo Corporation | $49.43 | 2019 | |
| Merck Sharp & Dohme LLC | $46.55 | 2021-2025 | Vaxneuvance, Gardasil 9 |
| Cepheid | $34.60 | 2025 | Genexpert |
| Ironwood Pharmaceuticals, INC | $32.66 | 2024 | |
| Shire North American Group INC | $32.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.85 | 2019 | |
| Biomarin Pharmaceutical INC. | $23.24 | 2025 | Voxzogo 1.2mg |
| Ucb, INC. | $19.42 | 2025 | Bimzelx |
| Aytu Biopharma, INC. | $17.22 | 2024 | Karbinal |
| Cranial Technologies, INC | $15.93 | 2025 | Doc Band |
| Noven Therapeutics, LLC | $15.36 | 2023 | Xelstrym |
| Collegium Pharmaceutical, INC. | $15.21 | 2025 | Jornay Pm |
| Kaleo, INC. | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.